Partnering with the National Academy of Medicine's (NAM's) Action Collaborative on Countering the U.S. Opioid Epidemic, Delphi Behavioral Health Group is eager to provide a commitment toward the key areas of patient engagement, prevention and treatment. As a key stakeholder in the fight against the growing opioid epidemic, historically Delphi has been a resource for those battling opioid addiction.

With a full spectrum of treatment settings ranging from inpatient detoxification to outpatient care across several states, Delphi has positioned itself to meet the patient’s needs wherever our clients may be in the recovery process. Having various entry points into treatment allows Delphi to engage the patient congruently with their immediate needs, whether it be detoxification, residential treatment, or a harm reduction model, such as medication assisted treatment. Recognizing the spirit of collaboration as a prerequisite for success as the nation confronts the opioid epidemic, Delphi is committed to collaborating with entities that share our goals toward successful treatment.

We as an organization employ a varied array of treatment models focused on evidence-based research that treatment engagement is the best indicator for patient success. Our strong alumni program maintains an ongoing relationship with patients long after their initial engagement and encourages continued treatment. Our commitment extends to recognizing that co-occurring psychiatric disorders are a vital part of the patient’s treatment plan and ultimately affect the treatment outcome. The interactive interface between mental health and substance use disorders requires that the patient’s mood and anxiety symptoms be addressed, while they are receiving their substance use disorder treatment. To this end, Delphi addresses psychiatric comorbidity by ensuring contemporary psychiatric care is available to the patient, at all sites. We believe that this feature of our care uniquely positions Delphi as a resource for more complicated presentations.

With regard to expertise, Delphi’s commitment to directly confronting this epidemic is highlighted by the medical experts employed. Our medical directors maintain board certifications in addiction, they are considered thought leaders who implement innovative treatment initiatives within the company and in their respective communities. These experts hold faculty appointments at respected universities, frequently speak at national events, and provide support to the local communities. All are accessible as consultants for complicated clinical and medical conditions that may impact the patient’s care.

By providing medical expertise, entry points for treatment, and advancing the collective understanding of opioid use disorder through the experience of our treatment professionals and the patients, it is Delphi’s wish to provide support to the National Academy of Medicine within the framework of the Action Collaborative

We look forward to our partnership toward these goals.

Sincerely,

Neeraj Gandotra MD
Chief Medical Officer

Carol Boyer
National Director of Community and Government Partnerships

Delphi Behavioral Health Group